Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-09-05
2006-09-05
Balasubramanian, Venkataraman (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S343000, C514S231500, C546S133000, C546S187000, C546S276400, C546S279400, C544S111000
Reexamination Certificate
active
07101896
ABSTRACT:
The present invention relates to aryl olefinic azacyclic compounds and aryl acetylenic azacyclic compounds, including pyridyl olefinic cycloalkylamines and pyridyl acetylenic cycloalkylamines. The present invention also relates to prodrug derivatives of the compounds of the present invention.
REFERENCES:
patent: 5212188 (1993-05-01), Caldwell et al.
patent: 5217975 (1993-06-01), Wadsworth et al.
patent: 5219849 (1993-06-01), Lotti et al.
patent: 5276043 (1994-01-01), Lippiello et al.
patent: 5346906 (1994-09-01), Baker et al.
patent: 5510355 (1996-04-01), Bencherif et al.
patent: 5583140 (1996-12-01), Bencherif et al.
patent: 5597919 (1997-01-01), Dull et al.
patent: 5604231 (1997-02-01), Smith et al.
patent: 5616707 (1997-04-01), Crooks et al.
patent: 5616716 (1997-04-01), Dull et al.
patent: 5663356 (1997-09-01), Ruecroft et al.
patent: 5731323 (1998-03-01), Whittamore
patent: 5780437 (1998-07-01), Goulet et al.
patent: 5811442 (1998-09-01), Bencherif et al.
patent: 5824692 (1998-10-01), Lippiello et al.
patent: 5849764 (1998-12-01), Goulet et al.
patent: 5852041 (1998-12-01), Cosford et al.
patent: 5859004 (1999-01-01), Olesen
patent: 5861423 (1999-01-01), Caldwell et al.
patent: 5952339 (1999-09-01), Bencherif et al.
patent: 6890935 (2005-05-01), Dull et al.
patent: WO 94/08992 (1994-04-01), None
patent: WO 94/14805 (1994-07-01), None
patent: WO 95/03306 (1995-02-01), None
patent: WO 96/12711 (1996-05-01), None
patent: WO 97/01556 (1997-01-01), None
patent: WO 97/11072 (1997-03-01), None
patent: WO 98/25619 (1998-06-01), None
patent: WO 98/54181 (1998-12-01), None
patent: WO 99/00385 (1999-01-01), None
patent: WO 00/34276 (2000-06-01), None
patent: WO 99/32117 (2000-07-01), None
patent: WO 01/32264 (2001-05-01), None
Barnes, Peter J., “Molecules in Focus Nuclear Factor-KB,”Int. J. Biochem. Cell Biol., 29(6): 867-870 (1997).
Birtwistle, Jon, “The Role of Cigarettes and Nicotine in the Onset and Treatment of Ulcerative Colitis,”Postgrad Med J., 72: 714-718 (1996).
Ebadi, et al., “Neurotophins and Their Receptors in Nerve Injury and Repair,”Neurochem Int., 30(4/5): 347-374 (1997).
Hanisch et al., “Modulation of Hippocampal Acetylcholine Release: A Potent Central Action of Interleukin-2,”The Journal of Neuroscience, 13(8): 3368-3374 (1993).
Holladay, et al., “Neuronal Nicotinic Acetylcholine Receptors as Targets for Drug Discovery,”J. Med. Chem., 40(26): 4169-4194 (1997).
Jonakait, G. Miller, “Neural-Immune Interactions in Sympathetic Ganglia,”TINS, 16(10):419-423 (1993).
Madretsma, et al., “In-Vivo Effect of Nicotine on Cytokine Production by Human Non-Adherent Monomuclear Cells,”European J. of Gastroen&Hepat, 8(10): 1017-1020 (1996).
Madretsma, et al., “Nicotine Inhibits the in Vitro Production of Interleukin 2 and Tumour Necrosis Factor- α by Human Mononuclear Cells,”Immunopharmacology, 35: 47-51 (1996).
Matthys, P. & Billiau, A., “Cytokines and Cachexia,”Nutrition, 13: 763-770 (1997).
Olesen, et al., “Identification of Novel (Isoxazole)Methylene-1-Azabicyclic Compounds with High Affinity for the Central Nicotinic Cholinergic Receptor,”Bioorganic&Medicinal Chemistry Letters, 7(15): 1963-1968 (1997).
Olivo, et al., “Syntheses of New Open-Ring andhomo-Epibatidine Analogues from Tropinone,”J. Org. Chem., 64(13): 4966-4968 (1999).
Peacock, et al., “The Effect of Nicotine on Reproduction and Attachment of Human Gingival Fibroblasts in Vitro,”J. Periodontal, 64(7): 658-665 (1993).
Pullan, Rupert D., “Colonic Mucus, Smoking and Ulcerative Colitis,”Ann R. Coll. Sur Engl., 78: 85-91 (1996).
Pullan, et al., “Transdermal Nicotine for Active Ulcerative Colitis,”The New England Journal of Medicine, 330(12):811-815 (1994).
Sandborn et al., “Nicotine Tartrate Liquid enemas for Mildly to Moderately Active Left-Side Ulcerative Colitis Unresponsive to First-Line Therapy: A Pilot Study,”Ailment Pharmacol. Ther., 11 663-671 (1997).
Sartor, R. Balfour, M.D., “Pathogenesis and Immune Mechanisms of Chronic Inflammatory Bowel Diseases,”The American Journal of Gastroenterology, 92: 12 5S-11S (1997).
Secor, H. & Seeman, J., “The Preparation of ‘Elongated’ Nicotine Analogues,”Heterocycles, 24:6 1687-1698 (1986).
Silverstein et al., “Cigarette Smoking and Ulcerative Colitis: A Case-Control Study,”Mayo Clin. Proc., 69 425-429 (1994).
Van Dijk et al., “Nicotine Inhibits Cytokine Synthesis by Mouse Colonic Mucosa,”European Journal of Pharmacology, 278 R11-R12 (1995).
Wallace, J. & Chin, B., “Inflammatory Mediators in Gastrointestinal Defense and Injury,”Proc. Soc. Exp. Biol. Med., 214 192-203 (1997).
Yanina et al., Khim.-Karm, 21:7 808-811 (1987).
Zijlstra et al., “Effect of Nicotine on Rectal Mucus and Mucosal Eicosanoids,”Gut, 35 247-251 (1994).
Clementi, et al., “Neuronal nicotinic receptors, important new players in brain function,”European Journal of Pharmacology, 393: 3-10, (2000).
Cheng, et al., “Synthesis and Binding of 6,7,9,9-tetrahydro-5H-pyridio[3,4-d]azepine and related ring-opened analogs at central nicotinic receptors,”J. Med. Chem., 34: 177-190 (1999).
International Search Report for PCT/US02/13635, mailed May 20, 2003.
Bhatti Balwinder Singh
Dull Gary Maurice
Miller Craig Harrison
Schmitt Jeffrey Daniel
Balasubramanian Venkataraman
Targacept, Inc.
Womble Carlyle Sandridge & Rice PLLC
LandOfFree
Pharmaceutical compositions and methods for use does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pharmaceutical compositions and methods for use, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceutical compositions and methods for use will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3605681